Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 536-545 , November 2005

Renal cell carcinoma: Current status and future prospects

References 

  1. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611–1623
  2. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4:363–372
  3. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27:115–123
  4. American Cancer Society. Cancer facts and figures. American Cancer Society; 2003.
  5. American Cancer Society. Cancer facts and figures. American Cancer Society; 2004.
  6. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–1631
  7. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol. 1985;134:1094–1096
  8. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–205
  9. Godley PA, Ataga KI. Renal cell carcinoma. Curr Opin Oncol. 2000;12:260–264
  10. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352:1691–1696
  11. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987–989
  12. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  13. Marshall FF, Stewart AK, Menck HR. The National Cancer Data Base: report on kidney cancers. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1997;80:2167–2174
  14. Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4:385–390
  15. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136:376–379
  16. Bassil B, Dosoretz DE, Prout GR. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1985;134:450–454
  17. Guinan P, Sobin LH, Algaba F. TNM staging for renal cell carcinoma: Workgroup No. 3 – Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992–993
  18. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003;30:467–480
  19. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–1095
  20. Lee F, Patel HR. Kidney cancer: current management guidelines. Hosp Med. 2002;63:214–217
  21. Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med. 2002;53:393–407
  22. Dunn MD, Portis AJ, Shalhav AL, et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol. 2000;164:1153–1159
  23. El Galley R. Surgical management of renal tumors. Radiol Clin North Am. 2003;41:1053–1065vii
  24. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year follow-up. J Urol. 2000;163:442–445
  25. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162:1930–1933
  26. Itano NB, Blute ML, Spotts B, et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164:322–325
  27. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133–3140
  28. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214–1222
  29. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425–431
  30. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594–599
  31. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–2266
  32. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  33. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–970
  34. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–1076
  35. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177–186
  36. Kuebler JP, Hogan TF, Trump DL, et al. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep. 1984;68:925–926
  37. Fossa SD, Droz JP, Pavone-Macaluso MM, et al. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer. 1992;28A:878–880
  38. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859–2867
  39. Fossa SD, de Garis ST, Heier MS, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer. 1986;57:1700–1704
  40. Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol. 1991;9:832–836
  41. Hrushesky WJ, von Roemeling R, Lanning RM, et al. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990;8:1504–1513
  42. Bjarnason GA, Hrushesky WJ, Diasio R. Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell carcinoma (RCC): a phase III study. Proc Am Soc Clin Oncol. 1994;13:Abstract 233
  43. Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am. 2003;30:601–609
  44. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46(Suppl):S59–S65
  45. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol. 1999;161:381–386
  46. Warner E, Tobe SW, Andrulis IL, et al. Phase I–II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol. 1995;18:251–256
  47. Dexeus FH, Logothetis CJ, Sella A, et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol. 1991;146:709–713
  48. Bono AV. Steroid hormones and gormonal treatment in renal cell carcinoma. In:  deKernion J,  Pavone-Maculuso M editor. Tumors of the kidney. Baltimore (MD): Williams & Williams; 1986;p. 205–227
  49. Schacter L, Rozencweig M, Canetta R, et al. Megestrol acetate: clinical experience. Cancer Treat Rev. 1989;16:49–63
  50. Voravud N, Sriuranpong V, Lertsaguansinchai P. Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma. J Med Assoc Thai. 2000;83:123–128
  51. Collichio FA, Pandya K. Interferon alpha-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: a phase II study. Am J Clin Oncol. 1998;21:209–211
  52. Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control. 2002;9:293–304
  53. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993;20:283–295
  54. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14–7.
  55. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368–1375
  56. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  57. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907–913
  58. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694–704
  59. Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol. 1996;14:237–243
  60. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993;11:661–670
  61. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338:1272–1278
  62. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol. 1999;17:2039–2043
  63. Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928–1935
  64. Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol. 1997;158:1663–1674
  65. Voest EE, Kenyon BM, O’Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581–586
  66. Krown SE. Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987;59:647–651
  67. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255–1262
  68. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  69. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995;55:4182–4187
  70. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  71. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:1093s
  72. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a Phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:388s
  73. Stadler WM. New growth factor inhibitors crack code at cellular level to shut down signal transduction pathways. Kidney Cancer J. 2004;1:7–10
  74. George D, Michaelson D, Oh WK. Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2003;22:385;(Abstract 1548) – See also oral presentation at www.asco.org
  75. Fishman M, Antonia S. Novel therapies for renal cell carcinoma–an update. Exp Opin Investig Drugs. 2003;12:593–609
  76. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337
  77. Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003;14:483–494
  78. Gattinoni L, Alu M, Ferrari L, et al. Renal cancer treatment: a review of the literature. Tumori. 2003;89:476–484
  79. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  80. Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002;20:2017–2024
  81. Nelson RP, Logan TF, Abonour R. Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. Bone Marrow Transplant. 2002;30:805–812
  82. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463

PII: S0305-7372(05)00134-9

doi: 10.1016/j.ctrv.2005.07.009

Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 536-545 , November 2005

Article Tools

* Image Usage & Resolution